Ara
Toplam kayıt 5, listelenen: 1-5
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
(Elsevier Inc., 2022)
Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib ...
Convalescent plasma therapy in patients with COVID-19 (Letter)
(Pergamon-Elsevier Science Ltd, 2021)
[No Abstract Available]
Bortezomib-induced peripheral neuropathy and neuronopathy in patients with multiple myeloma
(Springer Heidelberg, 2013)
[No Abstract Available]
GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin's lymphoma.
(Amer Soc Clinical Oncology, 2019)
[No Abstract Available]
Turkish Acute Lymphoblastic Leukemia Registry, Retrospective Phase Data
(Amer Soc Hematology, 2019)
[No Abstract Available]